A novel approach to non-invasive and personalized skin cancer diagnosis
Sector: Hospital • Location: France
Source: EU Funding & Tenders Portal
French SME-company DAMAE Medical is facing skin cancer worldwide issue by developing the OCTAV Project, a new approach to dermatological diagnostic based on a disruptive Line-field Confocal Optical Coherence Tomography (LC-OCT) technology, in a novel hand-held imaging device. OCTAV is designed to capture in situ images of the skin layers with a cellular resolution. It is used in conjunction with d
Project Information FAQ
Project Information
Want to explore the full details? View the full report
Participants
Sponsoring Agency | Obfuscated Data |
Company | Obfuscated Data |
Status
Original status | ended |
Taiyo status | Obfuscated Data |
Taiyo last update | 00-00-0000 |
Available timestamps | 00-00-0000 |
Available timestamp type | Obfuscated Data |
Contact
Contact name | Obfuscated Data |
Phone | 0000000000 |
ObfuscatedData@email.com | |
Address | Obfuscated Data, Obfuscated data, obfuscated data, Obfuscated data |
Description
Description | French SME-company DAMAE Medical is facing skin cancer worldwide issue by developing the OCTAV Project, a new approach to dermatological diagnostic based on a disruptive Line-field Confocal Optical Coherence Tomography (LC-OCT) technology, in a novel hand-held imaging device. OCTAV is designed to capture in situ images of the skin layers with a cellular resolution. It is used in conjunction with dermoscopy to provide more accurate diagnosis, leading to fewer biopsies of benign lesions and earlier detection of melanoma (clinical use 1) and non-melanoma skin cancers (clinical use 2). It may also guide the surgery to provide more accurate presurgical margins (clinical use 3), preventing unnecessarily large scars and reducing the risk of recurrence. Correlatively, DAMAE is developing a full software solution, based on a data storage cloud-platform, a computer-aided software designed to assist dermatologists with OCTAV image interpretation, as well as telepathology and patient services. OCTAV device will initially be used by clinicians as a routine easy-handling diagnostic device in public practices (market segment 1). Implementation of OCTAV software will enable its adoption by a much larger market, consisting of private practices dermatologists (market segment 2). The approach will contribute to the development of skin cancer risk patient awareness, while changing the current paradigm through a timely, performant, and non-invasive approach, and releasing the financial burden on the healthcare system. Project OCTAV has successfully completed in 2017 a feasibility phase covered by the SME Instrument Phase 1, resulting in a TRL6 prototype of the technology and a first consolidated atlas of skin cancer clinical images. The main objective of this Phase2 is to scaleup the OCTAV solution to TRL9 through industrialization activities and by achieving a definitive market assessment, the clinical validation and the regulatory approval, before deploying the approach worldwide. |
Original sub-sector | Obfuscated |
Original Currency | USD |
Original budget | 000000000000000 |
Procurement method | Obfuscated Data |
Budget | 000000000000000 |
Location
Region | Obfuscated |
Country | Obfuscated |
State | Obfuscated Data |
County | Obfuscated |
Location | Obfuscated Data, Obfuscated data, obfuscated data, Obfuscated data |
Source
Source reliability | High |
Data quality score | 100% |
Source | Obfuscated Data |
URL | obfuscated_data,obfuscateddata.com |
More Details
Project Type | Obfuscated Data |
Article Published Date | Obfuscated Data |
